ArticlemAbs
Humatch - fast, gene-specific joint humanisation of antibody heavy and light chains.
Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Multi-objective antibody design and optimization using machine learning.Nature reviews bioengineering · 2026Article
- Discovery, Structural Characterization, and Preclinical Evaluation of Monoclonal Antibodies against Xylazine Poisoning.ACS pharmacology & translational science · 2026Article
- LICHEN enables light-chain immunoglobulin sequence generation conditioned on the heavy chain and experimental needs.Communications biology · 2026Article
- Germline-aware deep learning models and benchmarks for predicting antibody VH-VL pairing.mAbs · 2025Article
- HuAbDiffusion: a discrete language diffusion model used for antibody humanization.Briefings in bioinformatics · 2025Article
- Elucidation of B-cell specific drug immunogenicity liabilities via a novelFrontiers in immunology · 2025Article
- AI-based antibody design targeting recent H5N1 avian influenza strains.Computational and structural biotechnology journal · 2025Article
- p-IgGen: a paired antibody generative language model.Bioinformatics (Oxford, England) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibodies are a popular and powerful class of therapeutic due to their ability to exhibit high affinity and specificity to target proteins. However, the majority of antibody therapeutics are not genetically human, with initial therapeutic designs typically obtained from animal models. Humanization of these precursors is essential to reduce immunogenic risks when administered to humans.Here, we present Humatch, a computational tool designed to offer experimental-like joint humanization of heavy and light chains in seconds. Humatch consists of three lightweight Convolutional Neural Networks (CNNs) trained to identify human heavy V-genes, light V-genes, and well-paired antibody sequences with near-perfect accuracy. We show that these CNNs, alongside germline similarity, can be used for fast humanization that aligns well with known experimental data. Throughout the humanization process, a sequence is guided toward a specific target gene and away from others via multiclass CNN outputs and gene-specific germline data. This guidance ensures final humanized designs do not sit 'between' genes, a trait that is not naturally observed. Humatch's optimization toward specific genes and good VH/VL pairing increases the chances that final designs will be stable and express well and reduces the chances of immunogenic epitopes forming between the two chains. Humatch's training data and source code are provided open-source.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.